0001595097false00015950972025-02-142025-02-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 14, 2025

CORBUS PHARMACEUTICALS HOLDINGS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-37348

46-4348039

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

500 River Ridge Drive

Norwood, Massachusetts

02062

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 963-0100

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

Trading
Symbol(s)


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

CRBP

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 7.01 Regulation FD Disclosure.

On February 14, 2025, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) issued a press release announcing data from the ongoing Phase 1 dose escalation clinical trial for SYS6002 (CRB-701) conducted by the Company in the United States and the United Kingdom (the “Western study”), that is being presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (the “2025 ASCO GU”) on February 14, 2025. A copy of the press release is attached hereto as Exhibit 99.1.

The Company also updated its presentation used by management to describe its business. A copy of the presentation is furnished as Exhibit 99.2 and is incorporated herein by reference.

The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibits 99.1 and 99.2, is being furnished to the Securities and Exchange Commission (the “SEC”), and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

Item 8.01 Other Events.

On February 14, 2025, the Company announced data from the Western study that is being presented at the 2025 ASCO GU on February 14, 2025.

The Western study is being conducted in the United States and United Kingdom and is enrolling patients with metastatic urothelial cancer (mUC) and other solid tumors associated with Nectin-4 expression. These included several tumor types not previously explored in the corresponding Phase 1 dose escalation study being conducted in China (the “China study”) by the Company’s development partner, CSPC Pharmaceutical Group (“CSPC”). The China study enrolled patients with mUC and other solid tumors. Unlike the China study, participants in the Western study were recruited regardless of their individual Nectin-4 levels. The Western study opened for enrollment in April 2024 and the enrollment for dose escalation was completed in October 2024. A December 2024 data cut is being presented (n=38) of whom 26 participants were evaluable for efficacy. The Western study enrolled into the top four dose cohorts used in China (1.8, 2.7, 3.6 and 4.5 mg/kg) and adopted the same Q3W regimen.

Safety:

•
No dose limiting toxicities were encountered during the dose escalation phase of both studies.
•
CRB-701 was well tolerated with majority of treatment emergent adverse events being grade 1 or 2 in both studies.
•
Notably few cases of peripheral neuropathy or skin rash have been reported to date in either study:
o
Peripheral neuropathy: Western study (Grade 1-2: 5% (n=2/38), (Grade 3 or above: zero) was comparable to China study (Grade 1: 3% (n=1/37), Grade 2 or above: zero). The combined peripheral neuropathy rate for both studies was 4% (n=3/75).
o
Skin and subcutaneous disorders: 24% (n=9/38) in the Western study compared to 8% (n=3/37) in the China study. The combined rate for both studies was 16% (12/75) across all dose groups.
•
Ocular adverse events: implementation of a proactive, preventative ocular toxicity protocol in the Western study yielded a lower incidence of ocular adverse events in the 2.7 mg/kg and 3.6 mg/kg (doses selected for optimization) in the Western study (38%) compared to the China study (66%).
•
A single Grade 4 adverse event occurred in the Western study but was not related to CRB-701.

 

PK:

•
PK profile seen in the Western study was comparable to that generated in the China study. CRB-701 demonstrated a longer ADC half-life and lower free-MMAE exposure relative to enfortumab vedotin (EV).

 

Efficacy:

•
A total of 26 participants with eight tumor types were evaluable for efficacy at the time of this data cut.
•
Responses were observed in several tumor types including previously unexplored HNSCC tumors:
o
mUC: Western study (n=4), 1 PR, 1 SD, and 2 PD); China study (n=9, ORR 44%). Both mUC PD participants in the Western study were previously treated with EV.
o
Cervical: Western study (n=2, 1 CR and 1 PD); China study (n=7, ORR 43%).
o
HNSCC: Western study (n=7, 4 PR, 2 SD and 1 PD).

 

Nectin-4

•
The Western study did not have a Nectin-4 IHC threshold for inclusion.
•
Responses were also observed in participants with low H-scores for Nectin-4.
•
Data was in line with the pre-clinical data presented at AACR 2023 demonstrating sustained efficacy even in tumors with low H-scores for Nectin-4.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release dated February 14, 2025

99.2

Investor Presentation

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Corbus Pharmaceuticals Holdings, Inc.

Date:

February 14, 2025

By:

/s/ Yuval Cohen

Name: Yuval Cohen
Title: Chief Executive Officer

 

 

 

Exhibit 99.1

 

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

 

•
Study mirrored 4 highest doses used in China dose escalation study presented at ASCO 2024
•
Safety, tolerability and PK comparable to China dataset with no DLTs observed in either study
•
Low levels of peripheral neuropathy and skin toxicity observed in both studies
•
Clinical responses seen in urothelial (mUC) and cervical cancer participants in both studies
•
First time targeting of head and neck squamous cell carcinoma (HNSCC) with CRB-701 yields multiple responses
•
Dose optimization is underway with dosing at 2.7 mg/kg and 3.6 mg/kg Q3W

 

Norwood, MA, February 14, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) (“Corbus” or the “Company”), announced that data from its US and UK conducted first-in-human dose escalation clinical study (“Western study”) of CRB-701 (SYS6002) is being presented today at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).

 

The poster is titled Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 (SYS6002) in US and UK Patients with Urothelial Cancer and Other Solid Tumors (Perez, et al) and is being presented today between 11:30 am-12:45 pm PST. The poster will also be available on the Corbus website at the start of the poster presentation.

 

This Phase 1 Western dose escalation study enrolled participants with metastatic urothelial cancer (mUC) and other solid tumors associated with Nectin-4 expression. These included several tumor types not previously explored in China. Unlike the China study, participants were recruited regardless of their individual Nectin-4 levels. The Western study opened for enrollment in April 2024 and enrollment for dose escalation was completed in October 2024. A December 2024 data cut is being presented (n=38) of whom 26 participants were evaluable for efficacy. The Western study enrolled into the top four dose cohorts used in China (1.8, 2.7, 3.6 and 4.5 mg/kg) and adopted the same Q3W regimen.

The corresponding China Phase 1 first-in-human dose escalation study conducted by the Company’s development partner, CSPC Pharmaceutical Group (“CSPC”), enrolled participants with mUC and other solid tumors. The study opened for enrollment in January 2023 and concluded dose escalation in July 2024. Thirty-seven participants were enrolled and 25 were evaluable at time of April 2024 data cut presented at ASCO 2024. PK and dose expansion cohorts are being enrolled in China by CSPC.

 

Summary of data:

 

Safety

•
No dose limiting toxicities were encountered during the dose escalation phase of both studies.
•
CRB-701 was well tolerated with majority of treatment emergent adverse events being grade 1 or 2 in both studies.
•
Notably few cases of peripheral neuropathy or skin rash have been reported to date in either study:
o
Peripheral neuropathy: Western study (Grade 1-2: 5% (n=2/38), (Grade 3 or above: zero) was comparable to China study (Grade 1: 3% (n=1/37), Grade 2 or above: zero). The combined peripheral neuropathy rate for both studies was 4% (n=3/75).
o
Skin and subcutaneous disorders: 24% (n=9/38) in the Western study compared to 8% (n=3/37) in the China study. The combined rate for both studies was 16% (12/75) across all dose groups.
•
Ocular adverse events: implementation of a proactive, preventative ocular toxicity protocol in the Western study yielded a lower incidence of ocular adverse events in the 2.7 mg/kg and 3.6 mg/kg (doses selected for optimization) in the Western study (38%) compared to the China study (66%).
•
A single Grade 4 adverse event occurred in the Western study but was not related to CRB-701.

 

PK

•
PK profile seen in the Western study was comparable to that generated in the China study. CRB-701 demonstrated a longer ADC half-life and lower free-MMAE exposure relative to enfortumab vedotin (EV).

 

Efficacy

•
A total of 26 participants with eight tumor types were evaluable for efficacy at the time of this data cut.
•
Responses were observed in several tumor types including previously unexplored HNSCC tumors:
o
mUC: Western study (n=4, 1 PR, 1 SD and 2 PD); China study (n=9, ORR 44%). Both mUC PD participants in the Western study were previously treated with EV.
o
Cervical: Western study (n=2, 1 CR and 1PD); China study (n=7, ORR 43%).
o
HNSCC: Western study (n=7, 4 PR, 2 SD and 1 PD).

 

Nectin-4

•
The Western study did not have a Nectin-4 IHC threshold for inclusion.
•
Responses were also observed in participants with low H-scores for Nectin-4.
•
Data was in line with the pre-clinical data presented at AACR 2023 demonstrating sustained efficacy even in tumors with low H-scores for Nectin-4.

“I am encouraged by this emerging clinical data and its similarity to what has already been established for CRB-701 in China by our partner CSPC”, stated Dominic Smethurst, Chief Medical Officer of Corbus. “It is gratifying to see that the differentiated safety and tolerability profile has been replicated as have the efficacy signals in both mUC and cervical cancers. A new, previously unexplored potential benefit in HNSCC provides further impetus for us to continue the clinical development of this novel, differentiated ADC.”

 

“Emerging data for this novel Nectin-4 targeting ADC is promising, particularly for tumor types known to express Nectin-4 such as HNSCC”, stated Dr. Ari Rosenberg, Principal Investigator on this study and Assistant Professor of Hematology and Oncology at the University of Chicago. “There remains a substantial unmet need to not only enhance the targeted delivery of the cytotoxic payload, but also improve tolerability and reduce cumulative toxic effects. I am excited to see further data generated with this MMAE-based ADC.”

 

The dose optimization phase of the Phase 1 Western study has commenced. Participants are being randomized to the 2.7 mg/kg and 3.6 mg/kg cohorts in HNSCC, cervical and mUC tumors. More cohorts may be added to address additional tumor types.

 

About CRB-701

CRB-701 (SYS6002) is a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4, that contains a site-specific, cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload. Nectin-4 is a clinically validated, tumor-associated antigen in urothelial cancer.

 

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.

 

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

 

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential,” "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

 

All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.

 

INVESTOR CONTACT:

Sean Moran

Chief Financial Officer

Corbus Pharmaceuticals

smoran@corbuspharma.com

 

Bruce Mackle
Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com

 

Slide 1

Connecting Innovation to Purpose NASDAQ: CRBP Corporate Presentation February 14, 2025 Exhibit 99.2

Slide 2

This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities, including timing or completion of trials and presentation of data and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies. Forward-Looking Statements

Slide 3

Therapy Disease Indication Sponsor Pre-Clinical Phase 1 Phase 2 Phase 3 Milestones Next-Generation Nectin-4 targeting ADC CRB-701 Next-generation Nectin-4 targeting ADC Nectin-4 positive solid tumors CSPC (China) Multiple Cohorts Expanding Corbus (US + Europe) Dose optimization in mUC, HNSCC& cervical Anti-Integrin mAb CRB-601 Anti-⍺vβ8 mAb (TGFβ-targeting) ⍺vβ8 enriched solid tumors Corbus First Patient Dosed December 2024 Highly peripherally-restricted CB1R inverse agonist CRB-913 CB1 inverse agonist Obesity and related conditions Corbus FPI Expected in Q1-2025 A Diversified Pipeline with Differentiated Clinical Risk Profiles FDA Fast Track Designation Granted December 2024 (cervical cancer)

Slide 4

CRB-701 Next Generation Nectin-4 Targeting ADC

Slide 5

Extend ADC half-life  Reduce dosing frequency  Convenience Lower DAR + longer half-life  Dose higher than PADCEV® Efficacy Nectin-4 targeting ADC for treatment of solid tumors Safety Designing a Nectin-4 ADC Intended to Address PADCEV® Unmet Needs 

Slide 6

CRB-701: Next Generation Nectin-4 Targeting ADC MMAE = Monomethyl auristatin E ADCC = antibody-dependent cellular cytotoxicity. CDC = complement dependent cytotoxicity Source(s): Modified image from Corbus data on file; Corbus data on file Novel nectin-4 Antibody ADCC + CDC functionality Glutamine Focused Side chain conjugation Payload: MMAE Microtubule disruption Cathepsin-B Cleavage Site

Slide 7

CRB-701: Best-in-Class Dosing Regimen Source(s): Corbus data on file; PADCEV® Prescribing Information as of Dec 2023 CRB-701 Clinical Cycle Comparison Patient / Physician Convenience Combination Flexibility

Slide 8

Phase 1 Dose Escalation Studies: Trial Design KEY ELIGIBILITY Age ≥ 18 years Advanced urothelial carcinoma or Nectin-4 positive Advanced solid tumors ECOG 0-1 Adequate organ function Stable ongoing comorbidities  No active CNS metastasis ESCALATION DESIGN Bayesian Optimal Interval (BOIN) design with accelerated titration at DL-1 IV Q3W over a 21-day cycle 0.2 mg/kg 0.6 mg/kg 1.2 mg/kg 1.8 mg/kg 2.7 mg/kg (expanding) 3.6 mg/kg (expanding) 4.5 mg/kg KEY ENDPOINTS Safety/tolerability PK and Efficacy NEXT STEPS Continued expansion at 2 doses ESCALATION DESIGN Bayesian Optimal Interval (BOIN) design with accelerated titration at DL-1 IV Q3W over a 21-day cycle 1.8 mg/kg 2.7 mg/kg (dose optimization) 3.6 mg/kg (dose optimization) 4.5 mg/kg NEXT STEPS Dose optimization (Project Optimus) monotherapy in HNSCC, cervical, and bladder tumors: PD-1 combo cohorts 2025

Slide 9

Phase 1 Dose Escalation Studies: Key Characteristics Median age (range) 55 (35, 76) 62 (34, 90) Sex (M/F) 29.7%, 70.3% 42.1%, 57.9% ECOG PS 0,1, missing 8.1%, 89.2%, 2.7% 23.7%, 71.1%, 5.3%, 0% Weight in kg mean (range) 59.01 (36.0, 84.9) 67.9 (32.1 111.8) Prior therapies median (range) 4 (0,10) 3 (1,8) Creatinine clearance <60μ mol/L 29.7% 31.6% Visceral metastasis (Y/N/missing) 73%, 8.1%, 18.9% n.a. HbA1c <6.5% 97.3% 60.5% Primary tumor type n=37 n=38 Corbus tumor types (n=38) Urothelial 4 Cervical 4 TNBC/Breast 1 Endometrial 2 Prostate 1 HNSCC 9 Lung 5 Ovarian 5 Pancreatic 7 CSPC tumor types (n=37) Urothelial 13 Cervical 15 TNBC/Breast 5 CRC 1 Esophageal 2 Not assigned 1 Enrollment: CSPC primarily recruited patients with mUC and cervical tumors Corbus recruited wider range of patients with Nectin-4 expressing solid tumors

Slide 10

Phase 1 Dose Escalation Studies: TEAEs Summary of TEAEs ≥20% (n=37) Summary of TEAEs ≥ 15 % (n=38) Portion of patients (%) Portion of patients (%) Sources: CSPC data: ASCO 2024 Corbus data: ASCO GU 2025

Slide 11

AE Grade N of 37 Notes Skin rash 1 x Grade 1 1 x Grade 2 1 x Grade 3 3 (8.1%) All resolved PN 1 x Grade 1 1 (2.7%) Resolved AE Grade N of 38 Notes Skin rash 4 x Grade 1 4 (10.5%) Other skin AEs Pruritis (itchy skin) 5 x Grade 1 5 (13.2%) Blister 1 x Grade 1 1 x Grade 2 2 (5.3%) Rash maculopapular 1 x Grade 1 1 x Grade 2 2 (5.3%) Ulcer 1 x Grade 2 1 (2.6%) Dermatitis bullous (acral) 1 x Grade 3 1 (2.6%) Discontinued drug PN 2 x Grade 2 2 ( 5.3%) MedDRA broad search terms (Standardized MEDRA query: Neuropathy) Muscle weakness 1 x Grade 3 1 (2.6%) Secondary to disease progression Neuropraxia 1 x Grade 1 1 (2.6%) Motor vehicle accident Phase 1 Dose Escalation Studies: Few Skin and PN Events Sources: CSPC data: ASCO 2024 Corbus data: ASCO GU 2025 Peripheral neuropathy (PN): There were no PN exacerbations in 19 patients with a previous medical history of PN

Slide 12

Phase 1 Dose Escalation Studies: Low Rates of Dose Modifications Sources: Padcev data: NDA/BLA Multi-disciplinary Review and Evaluation – BLA 761137 PADCEV™ (enfortumab vedotin-ievx). Derived from Table 45 CSPC data: ASCO 2024 Corbus data: ASCO GU 2025 Dose Modification 1.25 mg/kg (n=300) 1.8-4.5 mg/kg (n=30) 1.8 mg/kg (n=13) 2.7 mg/kg (n=11) 3.6 mg/kg (n = 10) 4.5 mg/kg (n = 4) Discontinuation 55 (18.3%) 0 2 (15.4%)  0  2 (20%)  2 (50%)  Reduction 98 (32.6%) 0 0  1 (9.1%)  1 (10%)  0  Interruption 181 (60.3%) 1 (3.3%) 7 (53.8%)  4 (36.4%)  4 (40%)  2 (50%)  Discontinuations in Corbus study: Drug related: n =1 (acral bullous rash) Not drug related: n= 5 Corbus Dose Optimization (Project Optimus) Dose Cohorts

Slide 13

CSPC Dose Optimization PK Cohorts Corbus Dose Optimization Project Optimus Dose Cohorts Phase 1 Dose Escalation Studies: Ocular Toxicity is Manageable Sources: CSPC data: ASCO 2024, Corbus data: ASCO GU 2025 1.8 mg/kg N=3 2.7 mg/kg N=10 3.6 mg/kg N=14 4.5 mg/kg N=3 1.8 mg/kg N=13 2.7 mg/kg N=11 3.6 mg/kg N=10 4.5 mg/kg N=4 Eye disorders (all) 2 (66.7%) 5 (50%) 11 (78.6%) 2 (66.7%) 7(53.8%) 5 (45.5%) 3 (30%) 3 (75%) Grade 1 2 (66.7%) 1 (10%) 1 (7.1%) 0 5 (38.5%) 1 (9.1%) 0 0 Grade 2 0 4 (40%) 9 (64.3%) 2 (66.7%) 2 (15.4%) 2 (18.2%) 2 (20%) 3 (75%) Grade 3 0 0 1 (7.1%) 0 0 2 (18.2%) 1 (10%) 0 Grade 4 0 0 0 0 0 0 0 0 Grade 5 0 0 0 0 0 0 0 0 2.7 mg/kg and 3.6 mg/kg dose selected for PK and expansion cohorts by CSPC and dose optimization “Project Optimus” cohorts by Corbus: Use of prophylaxis + baseline selection in Corbus study  reduced ocular toxicity rates in 2.7 and 3.6mg/kg doses Total ocular AEs for 2.7 + 3.6 mg/kg cohorts in both studies : CSPC 16/24 (66%)  Corbus 8/21 (38%) No discontinuations due to ocular toxicity 66% 38%

Slide 14

Favorable Emerging Combined Safety Profile vs. Nectin-4-MMAE Peers Sources: 1.JCO, 2020 Apr 1; 38(10): 1041–1049, Rosenberg et al 2. NDA/BLA Multidisciplinary Review and Evaluation BLA 761137 PADCEV® (enfortumab vedotin) 3. Torras, O. Reig, et al. "652P BT8009 monotherapy in enfortumab vedotin (EV)-naïve patients with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1." Annals of Oncology 35 (2024): S515-S516.  4. ASCO 2024, Zhang, et al.  SGO plenary March 2024, Yang et al. 5 Combination of CSPC data ASCO 2024 and Corbus data ASCO GU 2025 Limitation PADCEV™ BT8009 9MW-2821 CRB-701 Upper dose limit 1.25 mg/kg1 5 mg/m3 1.25 mg/kg4 No DLTs up to  4.5mg/kg5 Schedule  D1, D8, D15 /28 days Q1W D1, D8, D15 /28 days Q3W ≥ Grade 3 AE rate 58% (n=179 of 310)2 53% (n=24/45)3 70%6  20% (n=15/75)5 Peripheral neuropathy 49% (n=76/155)1  36% (n=16/45)3   22.5% (n=54/240)4 4% (n=3/75)5 Rash (broad terms*) 45% (n=70/155)1 18% (n=8/45)3 30% (n=72/240)4 16% (12/75)5 Neutropenia (Gr 3) 6.8% (21/379)2 4% (n=2/45)3  27.9% (n=67/240)4 0%5 Dose reduction 30.3% (n=94/310)2 27% (n=12/45)3 Not released 3% (2/75)5 Dose interruptions  46.8% (n=145/310)2 53% (n=24/45)3 Not released 24% (n=18/75)5 *Rash (Broad terms): Rash and subcutaneous disorders SOC. Not including alopecia.

Slide 15

Company 21-day PK Comparison % ADC % Free MMAE Cmax AUC0-21d Cmax AUC0-21d PADCEV™ 1.24 mg/kg Q1W x 3 PADCEV™ Benchmark 100% 100% 100% 100% 2.7 mg/kg Q3W Matched for MMAE dose (DAR) 191% 251% 67% 56% 3.6 mg/kg Q3W 2.9-fold PADCEV™ ADC Dose 289% 405% 73% 73% 2.7 mg/kg Q3W Matched for MMAE dose (DAR) 191% 270% 40% 33% 3.6 mg/kg Q3W 2.9-fold PADCEV™ ADC Dose 235% 285% 92% 68% PK Data: Lower levels of MMAE for CRB-701 vs. PADCEV ® Sources: PADCEV® reference data from BLA761137 17 December 2019 CSPC data: ASCO 2024 Corbus data:on file

Slide 16

Phase 1 Dose Escalation Studies: Waterfall Plots *confirmed response Across all patients in waterfall plot ORR DCR Corbus (n=26) 27% 77% CSPC (n=25) 28% 68% SD* HNSCC patent with a clinical PR coded to SD because the target lesion was occluded by invasive aspergillosis. PD* Cervical patient with tumor shrinkage of -64.42% and overall assessment of PD is ongoing treatment with radiotherapy to the new lesion. muC Urothelial cancer patients with primary progressive disease previously treated with PADCEV™ 4/7 CR/PRs Confirmed and 3 unconfirmed response patients all currently in the study. CR, complete response; HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung cancer; PD, progressive disease; PDAC, pancreatic ductal adenocarcinoma; PR, partial response; Q3W, every 3 weeks; SD, stable disease; TNBC, triple-negative breast cancer Sources: CSPC data: ASCO 2024 Corbus data: ASCO GU 2025

Slide 17

Phase 1 Dose Escalation Studies: Swimmer Plots Sources: CSPC data: ASCO 2024, Corbus data: ASCO GU 2025, N=37, Data were unavailable for one patient (Infusion only no duration data). Best overall response is indicated at the end of each bar. Bold text indicates confirmed responses, all other responses are unconfirmed, no minimum duration was required for SD. CR, complete response; HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung cancer; PD, progressive disease; PDAC, pancreatic ductal adenocarcinoma; PR, partial response; Q3W, every 3 weeks; SD, stable disease; TNBC, triple-negative breast cancer.

Slide 18

Phase 1 Dose Escalation Studies: mUC Sources CSPC data: ASCO 2024: Patients dosed with >1.2mg/Kg, Corbus data: ASCO GU 2025 *Patient admitted with SAE of unrelated dyspnoea and presumptive PD in the liver. Patient excluded from Waterfall plot due to disease progression prior to first tumor assessment. % Change by RECIST criteria ORR: 44% (4 out of 9) DCR: 78% (7 out of 9) Response Dose (mg/kg) Nectin-4 H score Pre-treated with PADCEV® PD* (n.a) 1.8 Insufficient tissue Yes PD (+28.18%) 1.8 260 Yes, pending confirmation SD (+1.27%) 1.8 295 Yes cPR (-74.19%) 1.8 210 No ORR: 1 out of 4 (1 out of 2 for PADCEV®-naïve) DCR: 2 out of 4 (2 out of 2 for PADCEV® -naïve) Dose mg/Kg 3.6 3.6 2.7 3.6 4.5 3.6 2.7 3.6 1.2 Nectin-4 H score 205 0 105 N.A 271 220 190 293 175 CR, complete response; PD, progressive disease;; PR, partial response; SD, stable disease

Slide 19

Phase 1 Dose Escalation Studies: Cervical cancer Sources: CSPC data: ASCO 2024: for patients dosed >1.2mg/Kg Corbus data: ASCO GU 2025 ORR: 43% (3 out of 7) DCR: 86% (6 out of 7) ORR: 1 out of 2 DCR: 1 out of 2 Response Dose (mg/kg) Nectin-4 H score Notes PD (-61.42%) 1.8 205 Ongoing treatment with radiotherapy to a new lesion uCR (-100%) 2.7 20 Treatment ongoing % Change by RECIST criteria Dose mg/Kg 3.6 3.6 3.6 1.8 3.6 3.6 3.6 Nectin-4 H score 80 110 265 65 185 235 132 CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease

Slide 20

Corbus Phase 1 Dose Escalation Study: HNSCC Emerges As New Target Dose mg/kg 1.8 2.7 1.8 3.6 3.6 1.8 Nectin-4 H score 210 250 165 280 25 165 SD* HNSCC patent with a clinical PR coded to SD because the target lesion was occluded by invasive aspergillosis. CR, complete response; HNSCC, head and neck squamous cell carcinoma; PD, progressive disease;; PR, partial response; SD, stable disease Drug (HNSCC data) Company ORR DCR PADCEV™ 1 Pfizer 11/45 (23.9%) 56.5% Keytruda2 Merck 18% (2nd line) n.a. Petosemptamab3 Ph2 monotherapy Merus 27/75 (36% ) (2nd line ) 48/75 (64%) BCA101 Ph1 monotherapy4 Bicara 2 of 6 patients 5 of 6 Late stage/rescue therapies5 Various Methotrexate (4%) Cetuximab (11%) Paclitaxel (14%) CRB-7016 Corbus 4 of 7 patients 6 of 76 Swiecicki, Paul L., et al. "Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer." Journal of Clinical Oncology (2024): JCO-24. Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016 Jul;17(7):956-965. doi: 10.1016/S1470-2045(16)30066-3. Epub 2016 May 27. PMID: 27247226. Le Tourneau, C., et al. "411MO Petosemtamab (MCLA-158) monotherapy in previously treated (2L+) recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase II trial." Annals of Oncology 35 (2024): S1557-S1558. Bedard, Philippe L., et al. "A phase 1 trial of the bifunctional EGFR/TGFβ fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid tumors." (2022): 2513-2513. Lala, Mallika, et al. "Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): a systematic literature review." Oral oncology 84 (2018): 108-120. One patient excluded from Waterfall plot due to PD assessment prior to first tumor assessment resulting from disease progression. Corbus data: ASCO GU 2025 % Change by RECIST criteria

Slide 21

Prior therapies Carboplatin+docetaxel+5FU 3 weeks (PD) then Cisplatin 4 weeks (PD) then pembrolizumab 6 weeks (PD) then experimental bispecific antibody duration of Rx unknown (PD) HNSCC Case Study: Clinical Improvement in Patient with Resistant Disease Baseline tumor assessment 09/19/2024 6-week follow-up assessment 11/07/2024 61-year-old male patient with HNSCC had 6-week tumor assessment images  (uPR -57%). He was previously suffering with significantly reduced performance status (ECOG 2) and on supplemental oxygen, now riding his bicycle, off oxygen and has gained 15 pounds with an ECOG of 0. – USA Study investigator

Slide 22

What Does a Combined CSPC + Corbus Dataset Look Like for mUC + Cervical + HNSCC? Sources CSPC data: ASCO 2024 Corbus data: ASCO GU 2025 3.6 1.8 3.6 3.6 1.8 3.6 1.8 0.6 3.6 0.6 2.7 0.2 3.6 0,6 1.8 4.5 2.7 2.6 1.8 3.6 2.7 3.6 3.6 3.6 3.6 3.6 1.8 1.2 1.8 1.8 2 7 80 30 205 0 295 110 210 68 265 25 105 80 NA 92 42 271 250 220 165 185 190 235 280 235 293 25 205 175 210 210 20 Cervical Urothelial HNSCC CSPC patients Corbus patients Across all patients in combined waterfall plot ORR DCR 31 HNSCC, CC & mUC patients in US-UK/China 42% 84% SD* HNSCC patent with a clinical PR coded to SD because the target lesion was occluded by invasive aspergillosis. PD* Cervical patient with tumor shrinkage of -64.42% and overall assessment of PD is ongoing treatment with radiotherapy to the new lesion. CR, complete response; HNSCC, head and neck squamous cell carcinoma; PD, progressive disease; PR, partial response; SD, stable disease Dose mg/kg Nectin-4 H score

Slide 23

CRB-701 Corbus Study Design Dose escalation Project Optimus (Dose optimization) Dose expansion at RP2D Randomized to 2.7 or 3.6 mg/kg monotherapy in: HNSCC Cervical mUC mUC Non-UC tumors: A B C Basket of nectin-4 positive tumors Ongoing 1.8 mg/kg 2.7 mg/kg 3.6 mg/kg 4.5 mg/kg Randomized to 2 doses of CRB-701 + CPI

Slide 24

Indications of Interest: Source: SEER Bladder Cancer; Census.gov; Weir et al., 2021; American Cancer Society; Chu et al., 2022; Hoffman-Censits et al., 2022. SEER Cervical Cancer; Census.gov; Weir et al., 2021; American Cancer Society; Mizuho Analyst Report; Corbus Corporate Deck. SEER Oral Cavity & Pharynx Cancer; SEER Laryngeal Cancer; Census.gov; American Cancer Society; Sanders et al., 2022. US HCP Qualitative Primary Research, N=15, December 2024. LifeSci Consulting Analysis. Urothelial Cancer Cervical Cancer Head & Neck Squamous Cell Carcinoma 5-Year Survival Incidence Current Treatment Localized Regional Distant 72% 40% 9% Localized Regional Distant 88% 70% 39% Localized Regional Distant 86% 66% 37% Early-Stage Locally Adv or Metastatic 1L 2L Gem + Cis / Carbo Keytruda™ + PADCEV™ Immune Checkpoint Inhibitor Carbo + Paclitaxel + Beva +/- Keytruda™ Tivdak™ Single-Agent Chemo Keytruda™ + Platinum + Paclitaxel Single-Agent or Combo Chemotherapy Keytruda™ + Platinum + 5-FU

Slide 25

One dose in 21-day cycle (vs PADCEV™ Q1Wx3) Fewer reductions/interruptions/discontinuations vs PADCEV ® Convenience Promising emerging efficacy in HNSCC Responses in both cervical and PADCEV-naïve mUC cancer Efficacy Markedly fewer skin and PN AEs vs PADCEV® Prophylaxis reduces ocular tox from 66%  38% (China  US/UK Optimus) Safety + Tolerability CRB-701: Summary of Latest Data Dose Optimization (Project Optimus) underway In progress

Slide 26

CRB-913 Oral cannabinoid Type-1 inverse agonist for superior incretin therapy in obesity

Slide 27

Source(s): Targeting the endocannabinoid system in diabesity: Fact or fiction?, Drug Discovery Today, Deeba et al. Mar 2021. CB1 is a Well-Understood Receptor in Metabolism >9K papers in PubMed on CB1 and metabolism

Slide 28

Monlunabant CRB-913 Next-Generation CB1 Inverse Agonists are Peripherally Restricted Rimonabant Otenabant Ibipinabant Taranabant Source(s): Cinar et al 2020 First-generation (2000-2007) Next-generation (2020 onwards) Designed to target the brain with high BBB penetration  FDA rejection due to safety concerns (2007) Designed to be peripherally restricted with minimal BBB penetration  avoid safety issues 

Slide 29

Clinical Efficacy of Monlunabant vs Rimonabant: What Do We Know? * Sourcs: RIO North America (Pi Snuyer et al 2006) ** Novo PR Sept 2024 *** Crater et al 2023 N =345* N =346* N =60** N = 20*** Placebo-adjusted weight loss cross-trial comparison Change in weights (kg) Weeks

Slide 30

CRB-913: Designed to be a Best-in-class Next Generation CB1 Inverse Agonist Design Goals Best-in-class peripheral restriction Protect lean mass (muscle) Retain 1st gen efficacy Enhance efficacy of incretin analogs

Slide 31

Ibipinabant (2004-2008) JD-5037 (2012-2018) / CRB-4001 (2018-2021) Completed Phase IIb (Solvay/BMS) Small, lipid soluble molecule High BBB penetration Oral Same backbone as Inversago compounds (MRI/INV family) CRB-4001 (JD5037) licensed from Jenrin in 2018 Extensive pre-IND studies carried out PK didn’t support TPP Oral CRB-913 New IP published – patent coverage through 2043 PK profile optimized for TPP Favorable multi-species bioavailability (>50%) Lower mfg. cost vs. incretins Oral CRB-913 is the Outcome of a Multi-year Medicinal Chemistry Campaign

Slide 32

Source(s): *Morningstar et al Obesity Week poster 2024 CRB-913: Higher Degree of Peripheral Restriction Than Monlunabant or Rimonabant Cmax Brain concentration (ng/g) Dose CRB-913 Monlunabant Rimonabant 10 mg/kg 22 344 561 1:15 1:26 1:1.6 Cmax = 561 Cmax = 344 Cmax = 22 AUC = 3855 AUC = 265 1:15 Brain levels lean mice Rimonabant Monlunabant CRB-913 AUC Brain:Plasma ratio Dose CRB-913 Monlunabant Rimonabant 10 mg/kg 1:50 1:5 1:1

Slide 33

1. Incretin analog therapy for insensitive/intolerant/high-risk patients 2. Combination with oral incretin agonists  potentially enhances efficacy OR improve tolerability 3. “Induction/maintenance” model: goal to potentially maintain weight loss post incretin analog therapy CRB-913: Potential Clinical Usage and Supportive Pre-clinical Data

Slide 34

Source(s): Morningstar et al 2024 Obesity Week poster CRB-913: Dose Response Weight Loss Across Wide Range in DIO Mice Allometric scaling to humans: 30 mg/day to >450 mg/day Top weight loss observed: 38% for 80 mg/kg/day QD on day 28 Weight loss (%) by day 19 in DIO mice

Slide 35

CRB-913: Enhanced Combo Effect with Semaglutide or Tirzepatide Source(s): Company data on file. DIO mouse model with C57BL6/J mice (n=10) fed a continuous high fat diet for 22 weeks prior and during 18 days of treatment (Similar effect also seen when CRB-913 was combined with liraglutide) Body weight change (%) at day 18 All cohorts P < 0.001 compared with vehicle 5.2

Slide 36

CRB-913: Induction/Maintenance with Semaglutide Source(s): Obesity Week poster 2024 “Switch” ↓ Vehicle Sema  vehicle Sema  Sema Sema  CRB-913

Slide 37

Weight Loss from CRB-913 Driven by More Fat Loss than Semaglutide Sources: Obesity Week poster 2024 SemaSema SemaCRB-913 At day 41 (end of study period) Sema  Sema Sema  CRB-913 Difference Weight loss (%) -13.6 -17.1 ↑25% Fat change from baseline -3.65% -8.65% ↑2.3x Vehicle

Slide 38

Clinical Development Pathway to Determination of Dose Response Curve H1 2025 H2 ‘25 – H1 ‘26 H2 ’26 – H1 ‘27 2022-2023 2023-2024 2025-2026 (?) 25 mg/day 28-day (n=37) 10, 20 and 50 mg/day 16 wks (n=240) Additional dose response study (n=600) Ph1a SAD  MAD Ph1b Dose response study Phase 2

Slide 39

CRB-601 Potential “best-in-class” ⍺vβ8 mAb

Slide 40

CRB-601 has the Potential to Enhance Checkpoint Inhibition Focus on adopting a precision-targeted approach Novel mechanism to target TGFb in the tumor microenvironment Large opportunity potential if POC is validated

Slide 41

TGFβ Predicts Poor Clinical Outcomes in a Subset of Cancer Patients 0 25 20 15 10 5 0.0 0.2 0.4 0.6 0.8 1.0 N = 8,461 cancers, multiple cell types Time (years) Overall survival, % Immunogenomic subtypes in cancer Source(s): Thorsson, et al. The Immune Landscape of Cancer, Immunity. 2018; 48:817 C1 C2 C3 C4 C5 C6 WOUND HEALING INF-γ DOMINANT INFLAMMATORY LYMPHOCYTE DEPLETED IMMUNOLOGICALLY QUIET TGFβ DOMINANT TGFβ predominance gene signature Gene expression, immune cell quantification & network mapping 33 different cancer types / 8,000+ tumors

Slide 42

Targeting the Integrin ⍺vβ8 Represents a Novel Approach to Regulating TGFβ Source(s): Huang et al., 2021. Recent progress in TGFβ inhibitors for cancer therapy.

Slide 43

CRB-601 is Targeting Latent -TGFβ by Blocking the Integrin avb8 The integrin avb8 is expressed in the tumor microenvironment (TME) Latent-TGFb is also expressed in the TME CRB-601 is a blocking antibody preventing the interaction of these two proteins

Slide 44

mAbs Targeting TGFβ Activation in the Clinic Source(s): Company websites. Clinicaltrials.gov. Internal analysis. CRB-601 PF-06940434 SRK-181 ABBV-151 RG6440 MOA ⍺vβ8  ⍺vβ8   L-TGFβ GARP (TGFβ1)  L-TGFβ Clinical Stage Phase 1 Phase 1/2 –study completed December 2024 Phase 1 Phase 2 HCC (read-out in 2025) Expanded Ph2 trials into muC & NSCLC Phase 1 Indications Solid Tumors Solid Tumors Solid Tumors HCC Solid Tumors Type Monoclonal Antibody Monoclonal Antibody Monoclonal Antibody Monoclonal Antibody Monoclonal Antibody ROA IV IV IV IV IV

Slide 45

CRB-601 Enhances Anti-PD-1 Therapy in Checkpoint Inhibition Sensitive and Resistant Murine Tumor Models CRB-601: 10 mg/kg BIW Anti-PD-1: 10 mg/kg BIW 10 animals / group Animals randomized at 50-80 mm3 Comparisons across arms *p<0.05, ***p<0.001, ****p<0.0001 % TGI  MC38  EMT6 4T1 Anti-PD-1 54 -8 6 CRB-601 46 37 10 Combo 89 65 41 Resistant Checkpoint blockade sensitivity Sensitive MC38 (Inflamed Tumor) EMT6 (Excluded Tumor) 4T1 (Desert Tumor) *** **** **** *** * *** *** *** * Source(s): Corbus data on file

Slide 46

Blockade of ⍺vβ8 in Combination with Anti-PD-1 Increased TIL Populations in Immune Excluded EMT6 Tumors Source(s): Corbus data on file **** *** **** **** **** *** **** **** Ki67+CD4 T Cells Ki67+CD8 T Cells CD4 T Cells CD8 T Cells Tumor Size * *** * **** ** *** ** *** ** **** * **** * Treatment Days -14   0  3   6   10 Anti-PD-1, 10 mg/kg, IP CRB-601, 30 mg/kg, IP EMT6 orthotopic implantation PD readouts Tumor volume = 200 mm3 (when treatment initiated) *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 M1/M2 Ratio NK Cells ** ** **** **** * *

Slide 47

CRB-601 Reshapes The Landscape Of Effector T and NK Cells in MC38 Tumors Source(s): Corbus data on file

Slide 48

Applying a Proprietary Algorithm to Define the Clinical Focus for CRB-601 A multi-parametric, immune-focused algorithm has refined indications for CRB-601 The combination of immune features and gene expression profiles have identified 9 indications for clinical priority High Low Quartiles Source(s): Corbus proprietary analysis Clustered Tumor Types

Slide 49

Patient Selection Strategies will Enhance the Probability of Success Source(s): Corbus proprietary analysis: Log2 fold change of ⍺vβ8 expression as a ratio to normal tissue Prioritization of indications with differential gene expression vs. normal tissues will emphasize focus on the tumor potential of ⍺vβ8 Development of a NEW patient enrichment biomarker will assist in enriching for responses and addressing the right immune resistant patient population with CRB-601 NSCLC (TPS-100) Head &Neck (TPS-60) Ovarian (TPS-100) Stomach (TPS-0) Source(s): Corbus proprietary IHC data: Poster 1388 SITC 2023 Annual Meeting

Slide 50

Leadership Upcoming Catalysts Financials

Slide 51

Management Team Sean Moran, CPA, MBA Chief Financial Officer Corbus co-founder and Chief Financial Officer since 2014. Prior senior financial management experience in emerging biotech and medical device companies. Christina Bertsch Head of Human Resources Accomplished senior human resource executive providing strategic HR consulting services to both large and small businesses across a variety of industries. Yuval Cohen, PhD Chief Executive Officer, Director  Corbus co-founder and Chief Executive Officer since 2014. Previously the President and co-founder of Celsus Therapeutics from 2005. Dominic Smethurst, PhD Chief Medical Officer, MA MRCP  Dr. Smethurst, MA MRCP, joined Corbus as our Chief Medical Officer in February 2024. He most recently served as CMO of Bicycle Therapeutics. 

Slide 52

Board of Directors Amb. Alan Holmer Ret. Chairman of the Board More than two decades of public service in Washington, D.C. including Special Envoy to China; Former CEO of PhRMA. Winston Kung, MBA Director More than 20 years of senior financial, business development and investment banking experience; currently CFO of ArriVent. (NASDAQ:AVBP) Yuval Cohen, PhD Chief Executive Officer, Director  Corbus co-founder and Chief Executive Officer since 2014. Previous the President and co-founder of Celsus Therapeutics from 2005. Anne Altmeyer, PhD, MBA, MPH Director 20 years of experience advancing oncology R&D programs and leading impactful corporate development transactions; currently President & CEO of TigaTx. Yong (Ben) Ben, MD, MBA Director 25 years of oncology R&D experience across industry and academia. CMO of BridgeBio Oncology Therapeutics and former CMO of BeiGene. Rachelle Jacques Director More than 25-year professional career, experience in U.S. and global biopharmaceutical commercial leadership, including multiple high-profile product launches in rare diseases; Former CEO of Akari Therapeutics. (NASDAQ: AKTX) John K. Jenkins, MD Director Distinguished 25-year career serving at the U.S. FDA, including 15 years of senior leadership in CDER and OND. Pete Salzmann, MD, MBA Director 20 years of industry experience and currently serves as Chief Executive Officer of Immunovant (NASDAQ: IMVT), a biopharmaceutical company focused on developing therapies for patients with autoimmune diseases.

Slide 53

Corporate Milestones Dose first patient in Ph1 SAD/MAD: Q1-2025 Start Ph1B study: Q4-2025 Complete Ph1 dose escalation: Q4-2025 Present Western Ph1 dose escalation data: Q-12025 Complete dosing under Project Optimus and establish RP2D: Q4-2025 CRB-701 CRB-913 CRB-601

Slide 54

Investment Summary $159M Cash, cash equivalents and investments as of September 30, 2024. Approximately 12.2M Common Shares Outstanding (~13.2M Fully-Diluted Shares)   Nectin-4 targeting ADC for treatment of solid tumors Oral CB1R inverse agonist to treat obesity TGFβ blocker Anti-⍺vβ8 integrin mAb for treatment of solid tumors CRB-913 CRB-601 CRB-701

v3.25.0.1
Document and Entity Information
Feb. 14, 2025
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 14, 2025
Entity Registrant Name CORBUS PHARMACEUTICALS HOLDINGS, INC.
Entity Central Index Key 0001595097
Entity File Number 001-37348
Entity Tax Identification Number 46-4348039
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 500 River Ridge Drive
Entity Address, City or Town Norwood
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02062
City Area Code 617
Local Phone Number 963-0100
Entity Information, Former Legal or Registered Name Not Applicable
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol CRBP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Corbus Pharmaceuticals (NASDAQ:CRBP)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025 Corbus Pharmaceuticals 차트를 더 보려면 여기를 클릭.
Corbus Pharmaceuticals (NASDAQ:CRBP)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025 Corbus Pharmaceuticals 차트를 더 보려면 여기를 클릭.